Short Interest in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Drops By 31.5%

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the recipient of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 54,700 shares, a drop of 31.5% from the October 15th total of 79,900 shares. Based on an average daily volume of 181,100 shares, the short-interest ratio is presently 0.3 days. Currently, 4.1% of the shares of the company are sold short.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Price Performance

NASDAQ:SNOA traded down $0.02 during mid-day trading on Friday, hitting $2.56. The company’s stock had a trading volume of 15,310 shares, compared to its average volume of 159,561. The business’s fifty day moving average is $3.08 and its two-hundred day moving average is $1.35. The stock has a market cap of $3.43 million, a price-to-earnings ratio of -0.51 and a beta of 1.38. Sonoma Pharmaceuticals has a 1 year low of $2.52 and a 1 year high of $9.37.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.